Prasterone
CAS 53-43-0
Prasterone (CAS 53-43-0) is a Phase 4 pharmaceutical compound with 4 bioactivity targets and 832 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 98415.3196 nM | 50 | - |
| - | IC50 | 37087.3235 nM | 40 | - |
| - | Potency | 27376.122222222224 nM | 20 | - |
| - | Ki | 5580 nM | 5 | - |
| - | AC50 | 29738.766666666663 nM | 3 | - |
| - | EC50 | 6665 nM | 2 | - |
| - | Kd | 14.45 nM | 1 | - |
| Corticosteroid-binding globulin Secreted |
Ki | 5 | - | Homo sapiens |
| Sex hormone-binding globulin Secreted |
Kd | 7.84 | - | Homo sapiens |
| Glucose-6-phosphate 1-dehydrogenase Enzyme |
Ki | 5.21 | - | Homo sapiens |
| Glucose-6-phosphate 1-dehydrogenase Enzyme |
Ki | 5.96 | - | Trypanosoma brucei |
| Beta-glucuronidase Enzyme |
IC50 | 4.11 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Butterfly rash | 29 | 136.151 | 10067982 |
| Periorbital oedema | 29 | 93.082 | 10034545 |
| Off label use | 182 | 89.998 | 10053762 |
| Application site discharge | 13 | 72.118 | 10052162 |
| Photosensitivity reaction | 31 | 71.276 | 10034972 |
| Head discomfort | 27 | 63.324 | 10019194 |
| Swelling face | 39 | 54.837 | 10042682 |
| Vaginal discharge | 19 | 53.66 | 10046901 |
| Tinnitus | 33 | 51.609 | 10043882 |
| Feeling hot | 34 | 49.586 | 10016334 |
| Dehydroepiandrosterone increased | 5 | 40.648 | 10049482 |
| Tendon calcification | 7 | 39.831 | 10057888 |
| Cellulitis | 37 | 35.818 | 10007882 |
| Oestradiol increased | 6 | 33.883 | 10030231 |
| Progesterone increased | 5 | 32.378 | 10063272 |
| Headache | 97 | 31.792 | 10019211 |
| Therapeutic response unexpected | 18 | 30.536 | 10043417 |
| Hypothalamic pituitary adrenal axis suppression | 6 | 28.467 | 10074052 |
| Gonadotrophin deficiency | 4 | 23.673 | 10018516 |
| Vulvovaginal burning sensation | 7 | 23.541 | 10067641 |
| Granulomatous liver disease | 6 | 20.772 | 10018704 |
| Gastric infection | 8 | 20.58 | 10056663 |
| Breast tenderness | 7 | 20.25 | 10006313 |
| Heart rate increased | 29 | 20.018 | 10019303 |
| Blood testosterone free increased | 3 | 19.639 | 10053785 |
| Adrenocortical insufficiency acute | 7 | 19.584 | 10001389 |
| Extrasystoles | 9 | 19.092 | 10015856 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Glycine Receptor (All subtypes) | Inhibition | - | 11522328 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| PRASTERONE | 3143 | SU | MTHSPL |
| prasterone | 3143 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Prasterone used for in pharmaceutical contexts?
Prasterone (CAS 53-43-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Prasterone?
Prasterone has 832 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Butterfly rash, Periorbital oedema, Off label use, Application site discharge, Photosensitivity reaction. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Prasterone also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Prasterone (DHEA) with EU status "prohibited".
What clinical phase is Prasterone in?
Prasterone is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Prasterone?
Prasterone has 12 bioactivity rows in this page query. Rendered target entries include Corticosteroid-binding globulin, Sex hormone-binding globulin, Glucose-6-phosphate 1-dehydrogenase, Beta-glucuronidase.